Bluebird bio Inc (BLUE) Stock: Identifying Value and Future Vision

Bluebird bio Inc [BLUE] stock prices are up 7.65% to $4.08 at the moment. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The BLUE shares have gain 4.62% over the last week, with a monthly amount glided 7.37%, and seem to be holding up well over a long-time horizon.

From an analyst’s perspective:

Bluebird bio Inc [NASDAQ: BLUE] stock has seen the most recent analyst activity on February 24, 2025, when JP Morgan upgraded its rating to a Neutral. Previously, JP Morgan downgraded its rating to Underweight on November 15, 2024. On November 15, 2024, downgrade downgraded it’s rating to Neutral and revised its price target to $0.50 on the stock. JP Morgan downgraded its rating to a Neutral. HSBC Securities downgraded its rating to a Reduce. Morgan Stanley upgraded its rating to Equal-Weight for this stock on December 08, 2023, and upped its price target to $7. In a note dated October 17, 2023, Cantor Fitzgerald initiated an Neutral rating.

The stock price of Bluebird bio Inc [BLUE] has been fluctuating between $3.56 and $28.60 over the past year. Currently, Wall Street analysts expect the stock to reach $13.69 within the next 12 months. Bluebird bio Inc [NASDAQ: BLUE] shares were valued at $4.08 at the most recent close of the market. An investor can expect a potential return of 235.54% based on the average BLUE price forecast.

Analyzing the BLUE fundamentals

The Bluebird bio Inc [NASDAQ:BLUE] reported sales of 83.81M for trailing twelve months, representing a surge of 391.72%. Gross Profit Margin for this corporation currently stands at -0.43% with Operating Profit Margin at -5.96%, Pretax Profit Margin comes in at -5.66%, and Net Profit Margin reading is -5.66%. To continue investigating profitability, this company’s Return on Assets is posted at -0.65, Equity is -3.22 and Total Capital is -1.87. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -63.67.

Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 3.72 points at the first support level, and at 3.35 for the second support level. However, for the 1st resistance point, the stock is sitting at 4.44, and for the 2nd resistance point, it is at 4.79.

Ratios To Look Out For

It’s worth pointing out that Bluebird bio Inc [NASDAQ:BLUE]’s Current Ratio is 0.48. In addition, the Quick Ratio stands at 0.28 and the Cash Ratio stands at 0.24. Considering the valuation of this stock, the price to sales ratio is 0.47.

Transactions by insiders

Recent insider trading involved Colvin Richard A, Chief Medical Officer, that happened on Mar 03 ’25 when 584.0 shares were sold., Klima Thomas J completed a deal on Mar 03 ’25 to sell 500.0 shares. Meanwhile, President and CEO Obenshain Andrew sold 921.0 shares on Mar 03 ’25.

Related Posts